DIRUI(SZ:300396)2022-12-08 02:58Group 1: Company Overview and Investor Relations - The company is Changchun Dirui Medical Technology Co., Ltd., with stock code 300396 and abbreviation Dirui Medical [1] - The investor relations activity was conducted on August 21, 2015, in the company's conference room [3] - Participants included representatives from various funds, such as Bosera Fund and Guotai Junan [2][3] Group 2: Product Development and Sales Strategy - The company is currently registering the CM-240 fully automated chemiluminescence immunoassay analyzer and has over 30 chemiluminescence immunoassay reagents in small-scale R&D [3][4] - Sales for chemiluminescence products will utilize a distributor model, with a focus on building a sales team through internal selection and external recruitment [3][4] - The company plans to implement market promotion strategies based on product performance and market conditions [4] Group 3: Financial Performance and R&D Investment - In the first half of 2015, the company's R&D expenses increased significantly due to new product development and registration costs [5][6] - The R&D team has been developed over nearly 20 years, with a focus on multi-disciplinary talent to support product innovation [6] - The company reported a 33% increase in reagent product revenue in the first half of 2015, with urine-related reagent products also experiencing around 30% growth [7] Group 4: Future Directions and Market Expansion - The company aims to cover approximately 50% of hospital testing items and plans to expand into areas such as immunology, biochemistry, hematology, microbiology, POCT, and molecular diagnostics [6][7] - Future growth may involve exploring autonomous R&D or external acquisitions to enhance the technology and product line [7] - The company is actively considering stock incentive plans and employee shareholding schemes [7]